Journal ArticleDOI
Strategies to improve long-term outcomes after renal transplantation.
Reads0
Chats0
TLDR
Current antirejection therapy, including calcineurin blockers such as cyclosporine and tacrolimus, the interleukin-2 signal-transduction inhibitor sirolimus and the purine-synthesis inhibitor mycophenolate mofetil are discussed, which inhibits the proliferation of T cells and B cells.Abstract:
This article provides a comprehensive, up-to-date review of methods to prevent early and late renal-allograft loss and to improve long-term outcomes in patients. The authors focus particular attention on the problem of late graft loss and discuss current antirejection therapy, including calcineurin blockers such as cyclosporine and tacrolimus, the interleukin-2 signal-transduction inhibitor sirolimus, and the purine-synthesis inhibitor mycophenolate mofetil, which inhibits the proliferation of T cells and B cells.read more
Citations
More filters
Journal ArticleDOI
Reduced exposure to calcineurin inhibitors in renal transplantation.
Henrik Ekberg,Helio Tedesco-Silva,Alper Demirbas,Stefan Vitko,Björn Nashan,A. Gurkan,Raimund Margreiter,Christian Hugo,Josep M. Grinyó,Ulrich Frei,Yves Vanrenterghem,Pierre Daloze,Philip F. Halloran +12 more
TL;DR: In this paper, the authors evaluated the efficacy and relative toxic effects of four immunosuppressive regimens: cyclosporine, mycophenolate mofetil, and corticosteroids.
Journal Article
Reduced exposure to calcineurin inhibitors in renal transplantation.
Henrik Ekberg,Philip F. Halloran +1 more
TL;DR: A regimen of daclizumab, mycophenolate mofetil, and corticosteroids in combination with low-dose tacrolimus may be advantageous for renal function, allograft survival, and acute rejection rates, as compared with regimens containing dacluzumab induction plus either low- doses of cyclosporine or low- dose sirolimus or with standard-dose cyclosporaine without induction.
Journal ArticleDOI
HLA-Mismatched Renal Transplantation without Maintenance Immunosuppression
Tatsuo Kawai,A. Benedict Cosimi,Thomas R. Spitzer,Nina Tolkoff-Rubin,Manikkam Suthanthiran,Susan L. Saidman,Juanita Shaffer,Frederic I. Preffer,Ruchuang Ding,Vijay K. Sharma,Jay A. Fishman,Bimalangshu R. Dey,Dicken S.C. Ko,Martin Hertl,Nelson Goes,Waichi Wong,Winfred W. Williams,Robert B. Colvin,Megan Sykes,David H. Sachs +19 more
TL;DR: Five patients with end-stage renal disease received combined bone marrow and kidney transplants from HLA single-haplotype mismatched living related donors, with the use of a nonmyeloablative preparative regimen, and it was possible to discontinue all immunosuppressive therapy 9 to 14 months after the transplantation.
Journal ArticleDOI
Long-term renal allograft survival in the United States: a critical reappraisal.
TL;DR: The significant progress that has occurred over the last two decades in renal transplantation is mostly driven by improvements in short‐term graft survival but long‐term attrition is slowly improving and could lead to bigger advances in the future.
Journal ArticleDOI
Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection.
TL;DR: Reducing risk factors for patient death should be a major target to improve outcomes after renal transplantation and effort should be made to control cardiovascular diseases, malignancies and infections with improved use of immunosuppressive drugs.
References
More filters
Journal ArticleDOI
Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen
A. M. J. Shapiro,Jonathan R. T. Lakey,Edmond A. Ryan,Gregory S. Korbutt,Ellen L. Toth,Garth L. Warnock,Norman M. Kneteman,Ray V. Rajotte +7 more
TL;DR: The observations in patients with type 1 diabetes indicate that islet transplantation can result in insulin independence with excellent metabolic control when glucocorticoid-free immunosuppression is combined with the infusion of an adequate islet mass.
Journal ArticleDOI
Actively acquired tolerance of foreign cells.
TL;DR: In this article, the problem of how to make tissue homografts immunologically acceptable to hosts which would normally react against them has been studied in the context of early foetal life inoculation.
Journal ArticleDOI
Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996
Sundaram Hariharan,Christopher P. Johnson,Barbara A. Bresnahan,S. Taranto,Matthew McIntosh,Donald Stablein +5 more
TL;DR: There has been a substantial increase in short-term and long-term survival of kidney grafts from both living and cadaveric donors since 1988.
Journal ArticleDOI
Infection in Organ-Transplant Recipients
Jay A. Fishman,Robert H. Rubin +1 more
TL;DR: A primary goal in organ transplantation is the prevention or effective treatment of infection, the most common life-threatening complication of long-term immunosuppressive therapy, and the adverse effects of the antimicrobial drugs used for prophylaxis and therapy are studied.
Journal ArticleDOI
A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group
TL;DR: Tacrolimus is more effective than cyclosporine in preventing acute rejection in cadaveric renal allograft recipients, and significantly reduces the use of antilymphocyte antibody preparations.
Related Papers (5)
The Banff 97 working classification of renal allograft pathology
Lorraine C. Racusen,Kim Solez,Robert B. Colvin,Stephen M. Bonsib,Maria Castro,Tito Cavallo,Byron P. Croker,A. Jake Demetris,Cynthia B. Drachenberg,Agnes B. Fogo,Peter N. Furness,Lillian W. Gaber,Ian W. Gibson,Dennis Glotz,J. Goldberg,Joseph P. Grande,Philip F. Halloran,H.E. Hansen,Barry Hartley,Pekka Hayry,Claire M. Hill,Ernesto O. Hoffman,Lawrence G. Hunsicker,Anne S. Lindblad,Niels Marcussen,M. J. Mihatsch,Tibor Nadasdy,Peter Nickerson,T. Steen Olsen,John C. Papadimitriou,Parmjeet Randhawa,David C. Rayner,Ian S.D. Roberts,Stephen Rose,D. Rush,Luis Salinas-Madrigal,Daniel R. Salomon,Stale Sund,Eero Taskinen,Kiril Trpkov,Yutaka Yamaguchi +40 more